Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GWP42006 in Autism Spectrum Disorder
NCT03849456Phase 2Terminated
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jan 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidivarin in Autism Spectrum Disorder (ASD), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Number of Participants Who Experienced Severe Treatment-Emergent Adverse Events. Started Jan 2020; status: terminated.
02
Drugs
cannabidivarin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03849456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03849456.